Creative industrial group Evonik have announced ground construction of a new production plant for specialty polyamide 12 (PA12) powders.
Evonik Investment
The powders are used in medical technology and other areas, specifically allowing industrial production of high-tech components in 3D printing. The announcement means Evonik will increase its annual capacity for its Vestosint brand of PA12 powders by 50%. The amount invested lies in the mid-double-digit million euro range. The new plant is scheduled to come on stream at the end of 2017.
Dr. Ralph Sven Kaufmann, chief operating officer of Evonik, said: “Organic growth is an essential cornerstone of our long-term growth strategy, which is why we’re continually investing in new capacities and innovative products. With the Marl investment we’re also further consolidating our leading position as a supplier of polyamide 12 based high-performance polymers.”
Dr. Claus Rettig, chairman of the management board of Evonik Resource Efficiency, said: “Our polyamide 12 powders are targeted at highly attractive markets such as the coatings industry and additive manufacturing. We see strong potential for growth here. New production capacities in Marl will enable us to service the growing demand for specialty high-performance polymers.”